US9096596, 58

ID: ALA3674077

Chembl Id: CHEMBL3674077

PubChem CID: 86282366

Max Phase: Preclinical

Molecular Formula: C20H17ClF3N5O

Molecular Weight: 435.84

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1nc2c(c(-c3ccn[nH]3)n1)C[C@@H](C)N(C(=O)c1cccc(C(F)(F)F)c1Cl)C2

Standard InChI:  InChI=1S/C20H17ClF3N5O/c1-10-8-13-16(26-11(2)27-18(13)15-6-7-25-28-15)9-29(10)19(30)12-4-3-5-14(17(12)21)20(22,23)24/h3-7,10H,8-9H2,1-2H3,(H,25,28)/t10-/m1/s1

Standard InChI Key:  IKDSIXDWHJJKMA-SNVBAGLBSA-N

Associated Targets(Human)

P2RX7 Tchem P2X purinoceptor 7 (5534 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

P2rx7 P2X purinoceptor 7 (1132 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 435.84Molecular Weight (Monoisotopic): 435.1074AlogP: 4.43#Rotatable Bonds: 2
Polar Surface Area: 74.77Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 9.06CX Basic pKa: 2.27CX LogP: 3.80CX LogD: 3.79
Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.65Np Likeness Score: -1.35

References

1.  (2015)  P2X7 modulators, 
2. Rech JC, Bhattacharya A, Letavic MA, Savall BM..  (2016)  The evolution of P2X7 antagonists with a focus on CNS indications.,  26  (16): [PMID:27426304] [10.1016/j.bmcl.2016.06.048]